Clinical Trials Logo

Pulmonary Emphysema clinical trials

View clinical trials related to Pulmonary Emphysema.

Filter by:

NCT ID: NCT00716053 Withdrawn - Clinical trials for Advanced Upper Lobe Predominant Emphysema

Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema

Start date: December 2008
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of the 20 mL BLVR System in treating patients with advanced upper lobe predominant emphysema.

NCT ID: NCT00700934 Recruiting - Emphysema Clinical Trials

Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema

Start date: February 2005
Phase: N/A
Study type: Observational

The aim of this study is to describe the natural history of patients with alpha-1 antitrypsin associated emphysema and to figure out associated prognostic factors.

NCT ID: NCT00684892 Completed - Clinical trials for Heterogeneous Emphysema

Safety and Feasibility Study of the Chartis System With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR)

Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and feasibility of the Chartis System in measuring air flow and pressures in isolated lung compartments in emphysema patients prior to endobronchial lung volume reduction (ELVR).

NCT ID: NCT00683722 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Start date: March 20, 2008
Phase: Phase 2
Study type: Interventional

The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).

NCT ID: NCT00680056 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients

Start date: November 2007
Phase: Phase 4
Study type: Interventional

The primary objective is to comparatively evaluate the isolated effects of a long-acting beta2-adrenergic (formoterol fumarate 12µg b.i.d. via Aeroliser) and combined with a long-acting anti-cholinergic (tiotropium bromide 18µg o.d via Handihaler) on breathlessness, dynamic hyperinflation and exercise tolerance in patients with advanced, but stable, chronic obstructive pulmonary disease. The study hypothesis is that combining long acting bronchodilators with different action mechanisms would promote synergistic effects on clinical outcomes.

NCT ID: NCT00675454 Terminated - Clinical trials for Pulmonary Disease, Chronic Obstructive

Evaluating the Effects of Surgical and Non-Surgical Treatment Options in People With Emphysema

Start date: January 2000
Phase:
Study type: Observational

Emphysema is a lung disease that involves damage to the air sacs in the lungs and can lead to breathing difficulties. Treatment options for people with emphysema include pulmonary rehabilitation, lung volume reduction surgery, and lung transplantation. This study will observe people with emphysema to assess the effect of these treatment therapies on their quality of life and long-term health.

NCT ID: NCT00670007 Completed - Emphysema Clinical Trials

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Start date: April 2008
Phase: Phase 4
Study type: Interventional

This study is a continuation of the placebo-controlled study CE1226_4001 (NCT00261833) to evaluate the efficacy and safety of Zemaira® i.v. administration in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The long-term verification of a disease-modifying benefit of Zemaira® on the progression of emphysema will be assessed by volume-adjusted lung density, measured yearly by computed tomography (CT).

NCT ID: NCT00650559 Terminated - COPD Clinical Trials

Thorax Enlarging Surgery: a Novel Surgical Approach to Emphysema

TE
Start date: June 2004
Phase: N/A
Study type: Interventional

There is a growing population of end-stage COPD patients for whom surgical treatments like lung transplantation and lung volume reduction surgery are not possible. In such patients, size mismatch between large emphysematous lungs and a restricted chest wall is a major cause for the reduction of dynamic lung volumes and consequent dyspnea. We hypothesized that enlargement of the thorax would be a potential alternative strategy to volume reduction surgery as it may improve lung mechanics by resizing the chest to the lung and does not further deprive patients from lung tissue which is already scarce.

NCT ID: NCT00633776 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease

Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)

Start date: March 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effects of nebulized formoterol fumarate (Perforomist) to dry-powder inhaler formoterol fumarate (Foradil). Perforomist is a solution that is made into very fine spray (using a nebulizer) that is then breathed in over 10-15 minutes. Foradil is taken in a single quick, deep inhalation.

NCT ID: NCT00630227 Completed - Clinical trials for Homogeneous Emphysema

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of the 20 mL BLVR System in patients with homogeneous emphysema. Patients with upper lobe predominant emphysema initially screened for earlier Phase 2 studies but not enrolled before study enrollment closed are also eligible for participation.